Oxurion unlocks $1m from Atlas for diabetic macular oedema therapy
Oxurion has received €1m ($1.09m) in funding from Atlas as part of a subscription agreement with Atlas totalling up to €20.8m ($25m).
Oxurion has received €1m ($1.09m) in funding from Atlas as part of a subscription agreement with Atlas totalling up to €20.8m ($25m).
What's Your Reaction?
